Kim C, Lee SG, Yang WM, Arfuso F, Um JY, Kumar AP, et al
Novo Nordisk has cut its full-year forecast three times in 2025 as GLP-1 growth rates decelerated sharply
Before considering BPC-157, speak with a qualified provider who can review your medical history, symptoms, medications, treatment goals, and whether peptide therapy is appropriate for you
remission: When the provider documents Crohns disease in remission, assign the appropriate K50.x0 code (without complications, e.g., K50.00, K50.10, K50.80, K50.90)
Last year I went from stale and pale to a golden goddess
The "triple G" treatment targets GLP-1, GIP and glucagon, against one or two hormones for existing drugs